Pitches · 8:00–9:30 AM PT
RCE
Atandra Burman, CEO · atandra@rce.ai
AI-enabled optical wearable technology to diagnose severe coronary artery occlusion in symptomatic chest pain patients.
Round
$8.5M Priced Round @ $10M post
FDA milestone
FDA pivotal study enrolling, pre-submission completed
FDA timeline
Q3, 2026 (submission), Q1, 2027 (approval)
Other groups in round
HIP, private angels, Cedars Accelerator, Atlanta Technology Angels, Mentors Fund
DD package
yes
Traction: 4 issued patents, 2 late breaking clinical presentations (ACC, AHA), 1 commercial LOI
What they're looking for: Sales Execs, Customer Introductions
OsseoAnchor
Bernard Gantes, CEO · b.gantes@osseoanchor.com
Dental implant placed without a drill and healing in 3 weeks instead of 12 to 20.
Round
$1.5M Convertible Note @ $8M
Closed
0
FDA milestone
Feasibility testing, Thermal testing, Initial stability testing, Insertion in soft and hard bone testing
FDA timeline
18-20 Months
Other groups in round
None
DD package
Yes
Traction: Patents
What they're looking for: No
GliaMedical
Junwei Li, CEO · gliamedicalinc@gmail.com
The first effective treatment for intracerebral hemorrhage with a breakthrough endovascular flow modification mechanism.
Round
$1M Convertible Note @ $5M
Closed
0
FDA milestone
Pre-submission completed and FDA written letter received in Mar 2025
FDA timeline
PMA submission in 2030 as class III devices, and anticipated approval in 20231
Other groups in round
None
DD package
In preparation
Traction: Complete in-vivo animal proof-concept